Marinus Pharmaceuticals (MRNS) Upgraded to Buy by BidaskClub

Marinus Pharmaceuticals (NASDAQ:MRNS) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Other equities analysts have also recently issued research reports about the company. JMP Securities reissued an “outperform” rating and set a $11.00 target price (up previously from $5.00) on shares of Marinus Pharmaceuticals in a report on Tuesday, September 12th. Laidlaw assumed coverage on Marinus Pharmaceuticals in a report on Thursday, December 14th. They set a “buy” rating and a $18.00 target price for the company. Finally, ValuEngine cut Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st.

Marinus Pharmaceuticals (MRNS) traded down $0.54 during midday trading on Friday, reaching $8.16. The company had a trading volume of 810,976 shares, compared to its average volume of 2,234,005. Marinus Pharmaceuticals has a 12 month low of $0.83 and a 12 month high of $9.87. The firm has a market cap of $351.74, a PE ratio of -8.77 and a beta of 2.44.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.02.

In other Marinus Pharmaceuticals news, major shareholder Bain Capital Life Sciences Inv sold 1,272,547 shares of the stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $7.88, for a total transaction of $10,027,670.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.40% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp acquired a new position in shares of Marinus Pharmaceuticals during the third quarter valued at approximately $128,000. Citadel Advisors LLC grew its position in shares of Marinus Pharmaceuticals by 327.8% in the third quarter. Citadel Advisors LLC now owns 51,383 shares of the biopharmaceutical company’s stock valued at $301,000 after purchasing an additional 39,371 shares in the last quarter. Susquehanna International Group LLP purchased a new stake in shares of Marinus Pharmaceuticals in the third quarter valued at approximately $503,000. EAM Investors LLC purchased a new stake in shares of Marinus Pharmaceuticals in the third quarter valued at approximately $554,000. Finally, Iguana Healthcare Management LLC purchased a new stake in shares of Marinus Pharmaceuticals in the third quarter valued at approximately $1,027,000. 49.77% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/30/marinus-pharmaceuticals-mrns-upgraded-to-buy-by-bidaskclub.html.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply